Progress on Blood Test for Neuologic Diseases

Another stage of clinical validation has been completed on a neurodegenerative disease blood test designed to be used as a diagnostic tool in the early assessment of Alzheimer's disease, Parkinson's disease, and other degenerative diseases, including amyotropic lateral sclerosis (ALS), also known as Lour Gehrig's disease.

To date, 438 blood serum samples from normal individuals and patients with Lou Gehrig's, Alzheimer's, Parkinson's, and other neurologic diseases have been analyzed, with results concurring with previous positive results. The test, called NuroPro, is being developed by Power3 Medical Products, Inc. (The Woodlands, TX, USA) in collaboration with Stan Appel, M.D., chief of neurology services at the Methodist Hospital and professor of neurology at Baylor College of Medicine (Houston, TX, USA).

Power3 Medical continues to build a database of disease-specific samples and is now using biostatistic analyses to select the optimum panel of biomarkers from a group of 34 identified biomarkers, to provide the highest measure of sensitivity and specificity.

"The company intends to commercialize a generic neurogenerative disease test as well as three disease-specific tests,” noted Steven B. Rash, CEO of Power3 Medical. "Power3 projects that the ALS test will be the first test to be introduced to the market.”





Related Links:
Power3 Medical
Baylor College of Medicine